| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5c8af15af4401660858bbe5fba3091d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2318-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2018-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b67ebc490e8c31f12e0e2190d5ef0cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_920ddabaf2fd4d680783df83754d12ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d55b538a16d090edad87e91907199b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e80ba64254c025333510401d9d4815a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3378d29a1b2ad605469c19073166f6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b66fc104c71bc6739495204a320c217 |
| publicationDate |
2018-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018134279-A1 |
| titleOfInvention |
Novel fusion polypeptides specific for lag-3 and pd-1 |
| abstract |
The disclosure provides for fusion polypeptides specific for both immune checkpoints PD-1 and LAG-3, whereby the fusion polypeptides can be useful for generating a durable anti- tumor or anti-infection response. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors, or as anti- infection agents. The present disclosure also concerns methods of making the fusion polypeptide described herein as well as compositions comprising such fusion polypeptide. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptide and to methods for generation of such fusion polypeptide and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020021061-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020249041-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111533782-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022098662-A3 |
| priorityDate |
2017-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |